Cytokinetics (CYTK) Stock: Buy, Sell, or Hold?
CYTK - Cytokinetics Inc.
$65.62
-0.29 (-0.44%)
▼
5d:
-0.06%
30d:
-8.1%
90d:
-24.13%
HOLD
MODERATE Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 22, 2026 at $68.31 · last confirmed Sep 25, 2026
Strength: 6.6/10
Get Alerted When CYTK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CYTK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CYTK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CYTK is currently trading at $65.62, which is considered oversold relative to its 30-day fair value range of $66.77 to $75.11.
Technical Outlook: Technically, CYTK is in a strong uptrend. The price is currently testing key support at $64.25. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $109.90 (+67.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CYTK is in a strong uptrend. The price is currently testing key support at $64.25. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $109.90 (+67.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$66.77 -
$75.11
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
Protect Your Profits
Holding CYTK? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 67.5% below Wall St target ($109.90)
- NEUTRAL: Bottoming setup forming (55/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$66.77 -
$75.11
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$64.25
Resistance Level
$70.18
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.74
Wall Street Target
$109.90
(+67.5%)
Revenue Growth (YoY)
-57.1%
Share & Embed Analysis
Last updated: October 01, 2026 5:02 PM ET
Data refreshes hourly during market hours. Next update: 6:02 PM
Data refreshes hourly during market hours. Next update: 6:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CYTK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Fady Ibraham Malik
SELL
3500 shares
2026-04-21
Robert I Blum
SELL
7500 shares
2026-04-15
Andrew Callos
SELL
7449 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 55 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 50 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 54 HOLD |
|
IMCR
Immunocore Holdings Ltd |
STRONG BUY
17 analysts |
$63 | 74 BUY |
Advanced CYTK Option Strategies
Professional options setups generated by AI based on today's CYTK price and gamma walls.
